“This new patent adds an additional layer of protection, extending beyond families of patents we have covering Encage’s original design, including robotic handling, and guiding systems”, said Dr. Andre Faure, CEO of Trod Medical. “Our strong family of patents, combined with Encage’s superior clinical outcomes for men with prostate cancer, puts Trod Medical in a dominant position in this very significant and growing market.”
TROD Medical’s Encage is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation.
TROD Medical develops tools for use in the focal ablation of soft tissues. The company, founded in 2006 by Faure, has developed significant expertise in developing innovative ablation technologies, particularly radio frequency (RF) ablation devices.
Trod Medical’s proprietary product, Encage, is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation. The device represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, such as those with prostate cancer. TROD Medical is a private venture-backed company with headquarters in Leuven, Belgium, and facilities in the Tampa Bay, Fla., area and Paris, France.